Categories: News

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Jefferies Healthcare Conference
Presentation date: Wednesday, June 8, 2022
Presentation time: 2:30 PM ET
Location: Marriott Marquis, New York, NY

Goldman Sachs 43rd Annual Global Healthcare Conference
Dates: June 13-16, 2022
1×1 meetings only
Location: Terranea Resort, Ranch Palos Verdes, CA

JMP Securities Life Sciences Conference
Fireside Chat date: Thursday, June 16, 2022
Presentation time: 11:00 AM ET
Location: The Lotte New York Palace Hotel, New York, NY

Stifel’s 2022 Virtual Cell Therapy Summit
Dates: June 29-30, 2022

Live webcasts and archived replays of key presentations will be available on the Company’s website at https://ir.vorbio.com/news-and-events/events-and-presentations.

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Investors & Media
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com

Staff

Recent Posts

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

2 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

2 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

2 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

2 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

2 hours ago

PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics

BELFAST, Northern Ireland  , Jan. 12, 2026 /PRNewswire/ -- PulseAI, a rapidly emerging leader in…

2 hours ago